TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02616939

Intervention type: OTHER
Intervention: Cardiac CT scanning (with the SpotLight CT)
Description: Cardiac CT scanning
Study: NCT02931526

Intervention type: DRUG
Intervention: Tigecycline
Description: Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.

Intervention type: DRUG
Intervention: Tigecycline
Description: Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
Study: NCT00456014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
Study: NCT00943631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
Study: NCT03103646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Description: 100 mg Capsules for oral use, 200 mg/day. In a fed state
Study: NCT00456014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
Study: NCT04079608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLASH curriculum
Description: High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Health Education for Adolescents
Description: Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
Study: NCT03103646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (300 mg)
Description: 100mg Capsules for oral use, 300 mg/day. In a fasted state.
Study: NCT01520467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole (1mg/day), administered orally for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet /day administered orally for 18 months.
Study: NCT04451200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan Injection
Description: injections doses will be personalized by PK at days -7 and -4
Study: NCT03502915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 50% nitrous oxide/50% oxygen via Nitronox delivery device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100% oxygen via Nitronox delivery device
Study: NCT00699413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutrition education plus active supplement
Description: After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nutrition education plus inactive supplement
Description: After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste.
Study: NCT01280786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elesclomol Sodium
Description: Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
Study: NCT03286192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compassion cultivation training
Description: Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
Study: NCT02393820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: treatment will be given until progression or unacceptable toxicity .
Study: NCT00872274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sumatriptan 100mg
Study: NCT02634242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Si-Wu-Tang (SWT)
Description: The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Si-Wu-Tang (SWT)
Description: The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
Study: NCT02109289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept is a tumor necrosis factor antagonist
Study: NCT03301779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext Red Blood Cell Processing System
Description: Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
Study: NCT01107964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Omega-3-acid ethyl esters
Description: 1 gram capsule by mouth four times daily for 45 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo corn oil capsule
Description: 1 gram by mouth 4 times daily for 45 days
Study: NCT01022229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Compound Natural Health Product
Description: * 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03534960

Intervention type: DEVICE
Group type: OTHER
Intervention: High Flow Nasal Oxygen Therapy
Description: Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal CPAP
Description: Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O
Study: NCT03324308

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography
Description: This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
Study: NCT00558558

Intervention type: DRUG
Group type: OTHER
Intervention: Haelan
Description: 4 oz orally twice daily for 8 Weeks
Study: NCT02510196

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reminder
Study: NCT02221791

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pure Epicatechin
Description: Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavan-3-ol cocoa
Description: Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
Study: NCT02945163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir Disoproxil Fumarate
Study: NCT01351311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance Training exercise with swiss ball

Intervention type: OTHER
Group type: OTHER
Intervention: Drug treatment
Description: Drug treatment
Study: NCT02945163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir Disoproxil Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz
Study: NCT04095702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Pacifier
Description: The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Weighted Pacifier
Description: The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
Study: NCT01705340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study: NCT02221791

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 70g white chocolate + placebo capsules
Study: NCT01705340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study: NCT03046004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid for breast cancer screening
Description: Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard leaflet
Description: Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
Study: NCT02798601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypernatremia
Description: Serum Sodium goal: 150 - 155 milliequivalent/L.
Study: NCT00078442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
Study: NCT04568733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates exercise session
Description: The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking at 3.2 kph
Description: Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking at 4.8 kph
Description: Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
Study: NCT01744197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera (lidocaine 70mg/tetracaine 70mg)
Description: All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera (lidocaine 70mg/tetracaine 70mg)
Description: All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
Study: NCT01156870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR566658
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study: NCT01893632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01088997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone Lactate
Description: Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
Study: NCT03046017

Intervention type: DEVICE
Group type: OTHER
Intervention: tDCS
Description: Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
Study: NCT02174250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Description: On Day 1, istradefylline 1 × 40-mg tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg
Description: On Day 1, istradefylline 1 × 40-mg tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 300mg BID + istradefylline 40mg Day 8 only
Description: On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
Study: NCT01814514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol-trusopt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03046017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.

Intervention type: OTHER
Group type: OTHER
Intervention: Lidocaine cream
Description: Lidocaine cream will be applied to reduce pain sensitivity (analgesia).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine cream
Description: Lidocaine cream will be applied to reduce pain sensitivity (analgesia).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lidocaine cream
Description: Lidocaine cream will be applied to reduce pain sensitivity (analgesia).

Intervention type: OTHER
Group type: OTHER
Intervention: Control cream
Description: A neutral cream will be applied as a control.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control cream
Description: A neutral cream will be applied as a control.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control cream
Description: A neutral cream will be applied as a control.
Study: NCT00474825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
Study: NCT00232505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT00966069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent collection
Description: Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthcare worker home visit
Description: Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
Study: NCT02629614

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cala ONE Device
Description: The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala ONE Device
Description: The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
Study: NCT01705340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT03132558

Intervention type: DRUG
Intervention: Radiopaque Media

Intervention type: DRUG
Intervention: Radiopaque Media
Study: NCT01276548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genexol® 175mg/m2 plus Carboplatin 5 AUC